高级检索
当前位置: 首页 > 详情页

First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Sun Yat Sen Univ, Dept Hematol Oncol, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China [2]State Key Lab Oncol S China, Guangzhou 510060, Guangdong, Peoples R China [3]Sun Yat Sen Univ, Dept Med Oncol, Affiliated Hosp 5, Zhuhai, Guangdong, Peoples R China [4]Sun Yat Sen Univ, Dept Med Oncol, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China [5]Sun Yat Sen Univ, Dept Radiotherapy, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China
出处:
ISSN:

关键词: EFFECTIVE SALVAGE REGIMEN BARR-VIRUS-DNA T-CELL (NK)/T-CELL LYMPHOMA NASAL TYPE PHASE-II CHEMOTHERAPY IE RADIOTHERAPY FAILURE

摘要:
BACKGROUND: Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) is a distinct subtype of non-Hodgkin lymphoma in which the upper aerodigestive tract is the most commonly involved site. To date, optimal treatment strategies and prognosis for patients with ENKTL have not been fully defined. METHODS: This prospective study was conducted to evaluate the efficacy and safety profiles of first-line combined gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE ENKTL. The primary endpoints were the complete response rate, the objective response rate, and toxicities. Secondary endpoints were overall survival and progression-free survival. RESULTS: Twenty-seven patients with newly diagnosed ENKTL were enrolled and completed the entire course of treatment. At the end of treatment, the overall response rate was 96.3%, including 20 patients (74.1%) who attained a complete response and 6 patients (22.2%) who attained a partial response. No patients developed disease progression during therapy. Grade 1 and 2 toxicities were frequent during GELOX, but grade 3 and 4 toxicities were few, and no treatment-related deaths occurred. At a median follow-up of 27.37 months, 7 patients (25.9%) experienced disease progression, and 4 of those patients died of disease. The rates of 2-year overall and progression-free survival were both 86%, and patients who attained a complete response at the end of treatment had significantly longer progression-free survival (P = .012) and overall survival (P = .021) than patients who did not attain a complete response. CONCLUSIONS: The current results indicated that GELOX followed by involved-field radiation therapy can be an effective and feasible treatment strategy for patients with stage IE/IIE ENKTL of the upper aerodigestive tract. These results will require further investigation in larger prospective trials. Cancer 2013. (c) 2012 American Cancer Society.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2012]版:
大类 | 2 区 医学
小类 | 2 区 肿瘤学
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 肿瘤学
JCR分区:
出版当年[2011]版:
Q1 ONCOLOGY
最新[2023]版:
Q1 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2011版] 出版当年五年平均 出版前一年[2010版] 出版后一年[2012版]

第一作者:
第一作者机构: [1]Sun Yat Sen Univ, Dept Hematol Oncol, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China [2]State Key Lab Oncol S China, Guangzhou 510060, Guangdong, Peoples R China
通讯作者:
通讯机构: [1]Sun Yat Sen Univ, Dept Hematol Oncol, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China [*1]Sun Yat Sen Univ, Dept Hematol Oncol, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21381 今日访问量:0 总访问量:1221 更新日期:2025-02-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)